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Accelerated evolution of a minimal 63–amino acid dual 
transcription factor
Andreas K. Brödel1, Rui Rodrigues2, Alfonso Jaramillo2,3,4, Mark Isalan1*
Transcription factors control gene expression in all life. This raises the question of what is the smallest protein that 
can support such activity. In nature, Cro from bacteriophage  is one of the smallest known repressors (66 amino 
acids), and activators are typically much larger (e.g.,  cI, 237 amino acids). Previous efforts to engineer a minimal 
activator from  Cro resulted in no activity in vivo in cells. In this study, we show that directed evolution results 
in a new Cro activator-repressor that functions as efficiently as  cI in vivo. To achieve this, we develop phagemid- 
assisted continuous evolution (PACEmid). We find that a peptide as small as 63 amino acids functions efficiently 
as an activator and/or repressor. To our knowledge, this is the smallest protein activator that enables polymerase 
recruitment, highlighting the capacity of transcription factors to evolve from very short peptide sequences.
INTRODUCTION
DNA binding proteins that regulate transcription initiation and 
control gene expression are called transcription factors (TFs). The 
question of, “What is the smallest peptide that can function as a TF?” 
is a fundamental one, with broad implications for the evolution of 
gene regulation (1–3). However, the potential for a peptide to be a 
minimal TF depends on its function: whether it is an activator, a 
repressor, or has dual activity (table S1).
In bacteria, TFs usually recruit or block RNA polymerase to 
activate or repress genes of interest, respectively. Generally, repres-
sion is more straightforward to achieve because it only requires a 
DNA binding protein to occlude key motifs in a promoter or to block 
transcription elongation by “roadblock” (4). By contrast, activator 
TFs have to strike a balance between DNA binding, RNA poly-
merase recruitment, and RNA polymerase release to initiate tran-
scription efficiently (5). Consequently, activators and dual TFs might 
need to be larger and more complex than repressors (table S1). 
These include well-studied examples such as  cI (237 amino acids) 
from bacteriophage ’s genetic switch (fig. S1A) (6).
In this study, we set out to test the minimal size limits for TFs, 
and in particular whether activators or dual TFs could be made as 
small as the smallest known repressors. Viruses have some of the 
smallest functional TFs, and phage  Cro protein is one of the smallest 
TF repressors characterized to date, containing only 66 amino acids 
(7, 8). Cro controls the viral life cycle along with  cI, and together, 
they function naturally as a toggle switch (fig. S1B) (6). Other exam-
ples of very small repressors are Cro from Enterobacteria phage P22 
(61 amino acids) (9) and CopG (45 amino acids) (10).
It has been previously shown that Cro might potentially be con-
verted into an activator by transferring the activating surface patch 
of  cI onto the surface of Cro (11). This can be done as molecular 
models of  cI and Cro suggest that  helices two and three of each 
protein lie in nearly identical positions. As a result,  helices of both 
TFs are positioned to interact with the same part of RNA polymerase, 
and Cro might become an activator if  helix two were suitably engi-
neered. However, a rationally engineered Cro variant had only a trace 
of detectable activity in vitro and none in vivo, in Escherichia coli, 
because of its low affinity for  operators (11). Cro is significantly 
smaller than common TFs [e.g., LacI, 360 amino acids; TetR, 
207 amino acids (table S1)], making it an ideal scaffold for developing 
a new set of small or minimal activators or dual TFs (fig. S1B). In 
addition, a set of Cro activators would complement the  cI synthetic 
biology toolbox (12) for gene circuit engineering in bacterial cells 
(13, 14), because cI and Cro function on related operators.
RESULTS
M13 phagemid-assisted continuous evolution
To obtain a set of small transcriptional activators derived from  Cro, 
we converted our phagemid-based batch selection system (12, 15) 
for accelerated continuous evolution in a manner similar to phage- 
assisted continuous evolution (PACE) (16, 17). One difference be-
tween our system and classic PACE is that we use phagemids rather 
than phage to facilitate screening large libraries. The smaller size of 
the phagemid enables the construction of gene libraries with a much 
higher number of variants than standard phage. We also prevent 
bystander mutations in phage genes by placing them on helper 
plasmids (HP) and accessory plasmids (AP), respectively (Fig. 1A). 
These plasmids are continuously replenished within fresh uninfected 
cells (Fig. 1B). The resulting phagemid evolution system, which we 
call phagemid-assisted continuous evolution (PACEmid), is based 
on conditional M13 bacteriophage replication. The selection process 
takes place inside E. coli cells by linking the evolving TF activity to 
restoring essential phage Gene VI expression (deleted from the HP). 
In this way, a TF with novel properties can be selected after several 
cycles of reinfection (Fig. 1B), and the process can be automated 
(Fig. 1, C and D).
For continuous selection, we found it essential to tune the basal 
Gene VI expression rate to produce sufficient amounts of phage in 
the absence of an active TF, reducing the chances of phage loss in 
the lagoon. We carried out model selections with cIopt [a  cI opti-
mized mutant with a strong activation region (18)] and showed that 
selection stringency and rate can be tuned by changing the copy 
number (19) of the AP (fig. S2). Furthermore, enrichment of cIopt 
was more efficient in continuous mode than in batch mode under 
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the same selection pressure (fig. S3), confirming the advantages of 
continuous selection (16, 17) for accelerated evolution.
We next implemented a mutagenesis device to expand the mu-
tation spectrum beyond combinatorial libraries. On ColE1-derived 
plasmids, such as our phagemid, the leading-strand replication pol I 
is gradually replaced by pol III over at least 1.3 kb downstream of 
the origin of replication (20). We therefore characterized the efficiency 
of three mutagenesis cassettes carrying error-prone pol I [EP pol I 
(21)] or error-prone pol III variants [MP4 and MP6 (22)] under the 
inducible promoters PBAD and PLlac (23). Mutation rates were then 
analyzed by a -lactamase stop codon reversion assay (fig. S4A), a 
rifampicin resistance assay (fig. S4, B and C), and by monitoring 
loss of red fluorescent protein (RFP) function on M13 phagemids 
after three rounds of batch evolution (fig. S4, D and E). The use of the 
MP6 (22) cassette under the isopropyl -d-1-thiogalactopyranoside 
(IPTG)–inducible promoter PLlac (PLlac-MP6-SpecR) led to the highest 
mutation rates, and this was chosen for downstream applications 
(fig. S4F). When induced with arabinose, the original MP6 leads 
to a 322,000-fold increase in mutation rate over that of wild-type 
(WT) E. coli. This results in an average of 6.2 × 10−6 substitutions 
per base pair (bp) per generation (22).
To validate the use of the adapted MP6 (22) mutator cassette for 
directed evolution, we first evolved an improved orthogonal  cI TF 
[cI4A5T6T,P; formerly the least active member of our cI toolkit (12)] 
(fig. S5A). The resulting cI variant had a Met-to-Thr mutation at 
position 42, leading to an improved dual activation-repression of 
green fluorescent protein (GFP) and mCherry (fig. S5B). The evolved 
cI4A5T6T,P (T42) up-regulated GFP expression 5.4-fold and led to a 91% 
repression of mCherry (fig. S5, C and D) (full sequences in the 
Supplementary Materials). In comparison, expression of the parental 
Fig. 1. PACEmid of TFs. (A) Plasmids: HP, helper phage to provide all phage genes except for gIII and gVI; AP, AP to provide conditional Gene VI expression to enable 
selection of a successful evolving TF variant; PM, phagemid containing an evolving TF variant and gIII; MP, A chemically inducible mutagenesis plasmid (MP) can, option-
ally, be used in addition to combinatorial library selection. (B) Continuous selection flow diagram: Host cells carrying the HP, AP, and, optionally, an MP continuously flow 
from a chemostat into a lagoon where they get infected with M13 phage. Only an active TF induces Gene VI expression to complete the phage life cycle, thus enriching 
this library variant; nonfunctional TF variants are diluted over time. Diversification of the target gene is obtained by combinatorial libraries and/or random mutagenesis. 
(C) Flow chart of the PACEmid continuous evolution system. E. coli cells (containing HP, AP, and MP) are cultured in the late log phase (chemostat, 37°C) and flow through 
a lagoon (30°C) containing the evolving phagemid (PM). (D) Photo of bioreactor setup showing three independent experiments performed in parallel (Photo credit: 
M. Mielcarek, Imperial College London).
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cI4A5T6T,P (M42) only displayed a 4.3-fold activation and a 58% re-
pression. Notably, position 42 was not randomized in our previously 
constructed  cI library and, thus, confirmed the potential of extra 
mutagenesis for improved protein activities.
Directed evolution of Cro activators
To see whether the optimized phagemid selection system was power-
ful enough to select a small Cro activator that could function in 
E. coli, we first constructed a bidirectional promoter (PCS/PM,CS), with 
three operator sites (O1, O2, O3) (Fig. 2A). O1 and O2 consisted of 
the  operator consensus sequence (CS), with the highest reported 
affinity for  Cro (24, 25). As Cro binds with a very high affinity 
to WT O3 (24), a mutated O3 site was used to reduce potential auto-
repression of the PM,CS promoter by  Cro. Basal promoter activity 
of PCS/PM,CS, as well as the effect of Cro on expression levels, was 
characterized by GFP and mCherry production and showed that WT 
Cro repressed in both promoter directions (Fig. 2, B and C).
To search for activators, a combinatorial library of Cro variants 
was constructed by randomizing four amino acids in  helix two 
and three (11) (Fig. 2D). Three residues (T17, K21, and D22) were 
in the potential activation patch, whereas the fourth residue (Y26) 
was upstream of the  helix necessary for DNA binding. We then 
constructed an AP with Gene VI under the engineered PM,CS pro-
moter, on the pSC101 vector for high selection stringency. The 
combinatorial Cro library was selected against this AP for 3 days 
in continuous culture, leading to a reproducible enrichment of Cro 
activators in two separate bioreactors (Fig. 2, E and F). The selected 
activators had at least three amino acid substitutions at the random-
ized positions over WT Cro (Fig. 3A). Notably, 10 of the 12 selected 
Cro activators contained an asparagine N at position 26. The im-
portance of N26 for activity was confirmed with site-directed muta-
genesis (fig. S6, A and B). The activity of the selected Cro activators 
(CroAct) was then analyzed with the reporter assay (Fig. 2A). CroAct 
variants up-regulated GFP expression 2.3- to 5.8-fold and repressed 
mCherry between 52 and 100% (fig. 3, B and C). In comparison, 
 cI expression resulted in a 6.7-fold activation and a 100% repression 
of the bidirectional PR/PRM promoter (fig. S6, C and D). The most 
active variants possessed the amino acids V17, A21, E22, and N26 
(CroAct3), and T17, V21, E22, and N26 (CroAct8) at the randomized 
positions; both were strong activators and inhibitors of the dual 
promoter in Fig. 2A.
Next, we explored a wider mutation space using the mutagenesis 
cassette (PLlac-MP6-SpecR). To achieve this, we applied continuous 
directed evolution for 4 days, using an optimized pLITMUS* vector 
backbone (fig. S7, A to C) and starting with the least-active variant 
CroAct10 (Fig. 3A and fig. S7D). Directed evolution was performed 
under a medium selection pressure (medium copy number plasmid 
pJPC12) compared to library selections (low copy pSC101; strong 
Fig. 2. Directed evolution of Cro dual TF activator-repressors. (A) Bidirectional promoter designed to activate GFP and repress mCherry. Operators: O1CS and O2CS sites 
recruit Cro; O3ob is designed to have weaker Cro binding. RNAP, RNA polymerase. (B) Despite obliterating the operator O3, expression of Cro still results in partial repression 
of GFP under the PM,CS promoter due to some affinity to the operator 3. (C) Cro binds with high affinity to the operators O1CS and O2CS as a dimer, resulting in a strong 
repression of mCherry. GFP and mCherry expression was normalized to OD600 (optical density at 600 nm), and data were obtained from four biological replicates. Error 
bars show 1 SD. (D) Structural model of WT Cro binding DNA, showing key residues (T17, K21, D22, and Y26) randomized in a combinatorial library (Protein Data Bank ID: 
6CRO). (E and F) Time course of the phage titer and enrichment of Cro activators during selection in continuous culture in two bioreactors. Samples were taken from the 
outflow of each bioreactor, and phage supernatants were analyzed by infecting TG1 cells carrying the reporter plasmid. Cro activators up-regulate GFP and repress 
mCherry, which can be monitored by plate analysis (enrichment of Cro activators). cfu, colony-forming units. a.u., arbitrary units.
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selection pressure). This resulted in higher phage production rates 
and, thus, an increased number of Cro variants. Five additional Cro 
activators were, thus, evolved with single amino acid changes in the 
polymerase interaction site (CroAct13 to CroAct16) or DNA binding 
 helix (CroAct17) (Fig. 3, D to F). Notably, a new amino acid change 
at position 31, N31S in the DNA binding  helix of CroAct17, had a 
strong impact on the TF activity. To summarize, we obtained a set 
of 17 small Cro activators with a broad range of activities.
Gene network engineering based on Cro activators
To test the potential for gene network engineering with the evolved 
Cro activators, we selected CroAct3 (5.3-fold activation, 100% repres-
sion) for use in combination with our set of orthogonal cI variants 
(12). Successful combination would allow the construction of a wide 
range of gene networks that integrate multiple inputs for activation 
and/or repression, based on variants of commonly used  promoters. 
First, we verified the lack of cross-reactivity of the CroAct3 to any of 
the synthetic promoters of the orthogonal cI toolkit (fig. S8). Having 
found no unwanted cross-reactivity, we built two different gene cir-
cuits. In the first network, gradual addition of arabinose resulted in 
expression of CroAct3 and, thus, a concentration-dependent increase 
in GFP and a decrease in mCherry, as expected (Fig. 4, A and B). 
Note that arabinose addition generally leads to an induction of more 
cells rather than increased levels of all cells as the PBAD promoter has 
an all-or-nothing response (26). In the second circuit, expression of the 
two orthogonal TFs CroAct3 and cI5G6G,P, linked to the inducers arab-
inose and 3OC6-HSL, resulted in a concentration-dependent increase 
in the reporters GFP and mCherry, as designed (Fig. 4, C and D). There-
fore, CroAct3 can be used for gene circuit engineering, either alone or in 
combination with other orthogonal TFs, and can target unidirectional 
as well as bidirectional promoters in a concentration- dependent manner.
Rational engineering of a minimal 63–amino acid dual TF
At 66 amino acids, CroAct3 already had a claim to being the smallest 
activator and dual TF that enables polymerase recruitment. However, 
we sought to push the boundaries of the smallest possible such TF. 
By identifying functional breakpoints in the expected structure 
(Protein Data Bank ID: 6CRO), we made targeted deletions to the 
C-terminal end of the TF and analyzed the variants using our re-
porter assay (Fig. 5A). Thus, we found that a minimal 63–amino 
acid protein (CroAct3 63aa) is still capable of transcriptional activation 
or repression in E. coli (4.4-fold activation, 88% repression) (Fig. 5, 
B and C). To our knowledge, this makes it the smallest dual TF that 
enables polymerase recruitment.
DISCUSSION
We chose to evolve  Cro because of its small size, its biological 
function as counterpart to  cI, and its use in numerous synthetic 
biology projects (27–30). Furthermore, Cro’s  helix two is positioned 
to be able to interact with the same part of RNA polymerase that 
 cI binds. The evolved Cro activators described in this study can easily 
Fig. 3. Analysis of Cro dual TF activator-repressors. (A) Sequencing results of 12 selected dual Cro activators. WT amino acids are highlighted in orange, and non-WT 
amino acids in green. (B and C) Activation and repression of the bidirectional promoter PCS/PM,CS by the selected Cro variants. GFP and mCherry expression was normal-
ized to OD600. (D) Sequencing results from continuous directed evolution using the mutagenesis plasmid on least-active variant CroAct10. (E and F) Activation and 
repression of the bidirectional promoter using the variants in (D). All data represent the average of four biological replicates, and error bars correspond to the SD between 
the measurements.
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Fig. 4. Synthetic gene circuits based on the evolved minimal activator CroAct3. (A) Design of a one-input gene network on a bidirectional promoter. The arabinose 
(Ara)–inducible sensor induces CroAct3 operating on a bidirectional promoter and two reporter genes. Operators: O1CS and O2CS sites (orange) recruit CroAct3; O3ob (white) 
is an obliterated site to circumvent TF binding. (B) Experimental data for the one-input system showing the concentration-dependent response of GFP and mCherry. 
(C) Design of a two-input gene network on two unidirectional promoters. Two sensors (PBAD and PLux*) act on an integrating circuit with two orthogonal TFs (CroAct3 
and cI5G6G,P) operating on two unidirectional promoters and two reporter genes. Operators: O1CS and O2CS sites (orange) recruit CroAct3; O15G6G and O25G6G sites (green) 
recruit cI5G6G,P; O3ob (white) is an obliterated site to circumvent TF binding. (D) Experimental data for the two-input system illustrating the concentration-dependent 
response of GFP and mCherry to the inducers (Ara, 3OC6). All data represent the average of three biological replicates, and error bars correspond to the SD between 
the measurements.
Fig. 5. Engineering of a minimal 63–amino acid dual TF. (A) Functional breakpoints were identified in the sequence of CroAct3, including a potential structure-breaking 
Pro59, a positive charge patch ending at Lys63, and a potentially neutral C-terminal Ala66 (bold). The corresponding truncation mutants [59, 63, and 65 amino acids (aa)] 
were generated; CroAct3 63aa is shown as an example. Activator mutations to WT  Cro repressor are highlighted in green. (B and C) Activation and repression of the 
bidirectional promoter PCS/PM,CS by truncated CroAct3 variants. GFP and mCherry expression were normalized to OD600; four biological replicates; error bars represent 
SD between the measurements. Activation and repression were normalized to the basal expression of each promoter in the absence of any TF on the PM. (D) Model 
indicating key features of the minimal dual TF, CroAct3 63aa.
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be constructed by site-directed mutagenesis of WT  Cro, providing 
a straightforward approach for users to implement these Cro variants 
into their synthetic biology projects (components are provided in 
figs. S9 to S11 and tables S2 to S6).
One basic scientific question that we address in this study is 
whether a small protein repressor can be converted into a transcrip-
tional activator in vivo. Overall, we conclude that not only is this 
possible but also that even 63 amino acids are sufficient to carry 
out dual intracellular transcriptional repression and activation by 
polymerase recruitment (~4.4-fold). It should be noted that TFs are 
distinct from DNA binding domains (DBDs). For example, certain 
zinc fingers can form functional DBDs, such as the 63–amino acid 
domain from GAGA factor [a single zinc-finger unit flanked by two 
basic rich regions (31)]. However, these interactions are not capable 
of transcription activation, and the full-length GAGA factor TF is 
519 amino acids. A potential alternative to our engineered dual TF is 
the Arc protein (53 amino acids) from bacteriophage P22, which can 
act as a repressor or activator (~2.8-fold) (32). However, activation 
does not occur here by recruiting a polymerase but via accelerating 
the rate at which the polymerase clears the promoter.
In this study, we used a powerful combination of rational design 
and directed evolution to obtain a set of Cro activators. An alterna-
tive strategy is to simply use directed evolution in the absence of a 
starting library. This would be very interesting as such an approach 
would lead to detailed information on specific evolution trajectories. 
In addition, this might give a time frame on how long it would take 
to walk through sequence space to obtain these beneficial mutations. 
Last, it would be interesting to further investigate whether our de-
veloped directed evolution platform can be easily transferred to evolve 
other small repressor peptides.
The small size of TFs raises interesting questions for the de novo 
evolution of DNA binding and polymerase-recruiting proteins from 
inert protein scaffolds. Cro belongs to the helix-turn-helix (HTH) 
superfamily (33), and this study implies that a relatively small amount 
of secondary structure, including three short  helices and three 
 strands, is sufficient to make a compact scaffold that could support 
minimal gene activation. As long as there are many ways to reach 
similar folds, the subsequent number of mutations to make a TF 
may be more tractable for natural selection [~11 mutations for DNA 
binding (34) and ~2 to 5 more for transcription activation]. We note 
that in yeast, a nine–amino acid peptide is sufficient for transactivation 
(35). Overall, this implies that short peptide scaffolds may have a 
greater capacity to evolve into DNA binding and RNA polymerase–
recruiting proteins than previously thought.
MATERIALS AND METHODS
Strains and media
Standard DNA cloning was performed with chemically competent 
TOP10 cells (Invitrogen) and electrocompetent TG1 cells. Combi-
natorial library cloning was performed with NEB 5-alpha electro-
competent cells. Phage production was carried out with TOP10, 
S1030 (36), TG1, or BL21(DE3) cells. All phage-assisted infection 
assays and reporter assays were performed with TG1 cells. Genotypes 
of all strains are listed in table S2. Cells were grown in 2× TY medium 
[NaCl (5 g liter−1), yeast extract (10 g liter−1), tryptone (16 g liter−1)], M9 
minimal medium [Na2HPO4 (6.8 g liter−1), KH2PO4 (3.0 g liter−1), 
NaCl (0.5 g liter−1), NH4Cl (1.0 g liter−1), 2 mM MgSO4, 100 M 
CaCl2, 0.2% (w/v) glucose, 1 mM thiamine-HCl], or Super Optimal 
broth with Catabolite repression (SOC) medium (Sigma-Aldrich). 
Chloramphenicol (10 to 25 g ml−1), kanamycin (25 to 50 g ml−1), 
spectinomycin (25 to 50 g ml−1), ampicillin (50 to 100 g ml−1), tetra-
cycline (5 to 10 g ml−1), and carbenicillin (10 g ml−1) were added 
where appropriate. IPTG, d-glucose, or l-arabinose was added to the 
media to induce or repress the promoter PLlac (23) or PBAD.
Cloning and plasmid construction
Subcloning was carried out using Gibson Assembly (37). GFP (GenBank 
no. KM229386), RFP, and mCherry (UniProt no. X5DSL3) were used 
as reporters. The  Cro regulatory protein (UniProt no. P03040) was 
used as TF scaffold, and the rpoN promoter (PrpoN) was used to ex-
press the evolving gene on the phagemid. The stronger activator cIopt 
(18) contains three amino acid changes in the  cI gene (GenBank 
no. X00166) at positions 35 to 39 (SVADK to LVAYE). The change 
in copy number of APs (pSC101, pJPC12, and pJPC13) and the 
CroAct3,Y26 variant were obtained by site-directed mutagenesis. All 
mutagenesis plasmids [MP4 and MP6 (22); EP pol I and WT pol I 
(21)] were obtained from Addgene and recloned into a vector back-
bone carrying a spectinomycin resistance gene (SpecR) and a cloDF13 
origin of replication to make it compatible with the other plasmids 
of the directed evolution system. The AraC-PBAD cassette on MP6-
SpecR was replaced with the IPTG-inducible promoter PLlac (23) 
(PLlac-MP6-SpecR). For the construction of gene circuits, a modified 
version of the PLux promoter (PLux*) (14) was used to reduce basal 
expression levels. A degradation tag (AANDENYALVA) was fused 
to cI5G6G,P at the C-terminal site to decrease basal expression in the 
absence of an inducer. Promoters, ribosomal binding sites, and 
terminators were ordered as oligonucleotides (Sigma-Aldrich) or 
were obtained from previous studies (38, 39). The PM,CS promoter 
contained the mutated O3 sites TATAAATAGTGGTGATA (40) 
or ACAAACTTTCTTGTATA to bypass autorepression at high  cI 
concentrations. Plasmids were purified using the QIAprep Spin 
Miniprep Kit or the HiSpeed Plasmid Maxi Kit (QIAGEN). Nucleo-
tide sequences of all cloned constructs were confirmed by DNA 
sequencing (Eurofins Genomics). The DNA sequences of the syn-
thetic promoters are listed in fig. S9. All plasmids and selected 
primer sequences are listed in tables S3 to S5. Maps for each class 
of plasmid are highlighted in fig. S10.
Construction of a combinatorial Cro library
A combinatorial Cro library was cloned on the basis of forward and 
reverse primers carrying NNS codons (where S = G/C) at positions 
T17, K21, D22, and Y26, as described previously (table S6) (15). 
Primers were fused by polymerase chain reaction (PCR), and fragments 
were cloned into the linearized pLITMUS-PrpoN-Cro-PBBa_J23106-gIII 
vector by Gibson Assembly. Cells were transformed and plated on 
24-cm2 Nunc BioAssay Dishes (Thermo Fisher Scientific). Trans-
formation efficiency was estimated by colony counting of plated serial 
dilutions. The next day, colonies were harvested and phagemid DNA 
was purified. Ten clones were sequenced to confirm diversity of the 
library (table S6). Molecular graphics of TFs were obtained with 
UCSF Chimera (41).
Selection phage production
Selection phage production was performed in BL21(DE3) cells 
carrying HP-PS-gIII-gVI and pJPC13-PS-PT7-gVI or TOP10 
cells containing HP-PS-gIII. Cells were made electrocompetent, 
phagemids were transformed, and cells were grown overnight at 
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30°C, 250 rpm (Stuart Shaking Incubator SI500), in 2× TY medium 
supplemented with kanamycin (12.5 g ml−1), ampicillin (50 g ml −1), 
and chloramphenicol (12.5 g ml−1) where appropriate. For enrich-
ment assays, plasmids carrying cIopt and RFP were mixed in a ratio 
of 10−6 before transformation. IPTG (0.25 mM) was added to the 
BL21(DE3) culture after phagemid transformation to induce Gene 
VI expression. Samples were centrifuged for 10 min at 8000g, and 
supernatants were sterile filtered (0.22-m pore size, Millex-GV). 
Phage concentration was analyzed by TG1 infection of diluted phage 
stocks and colony counting on ampicillin plates.
Phagemid-assisted batch evolution
TG1 or S1030 cells carrying the helper phage HP-PS-gIII-gVI, 
a Gene VI–based AP, and, optionally, a mutagenesis plasmid were 
grown on agar plates (M9 or LB) supplemented with appropriate 
antibiotics. For TG1-based evolution, starter cultures were inoculated 
in 2× TY with appropriate antibiotics and grown for 5 to 6 hours at 
37°C until the OD600 (optical density at 600 nm) reached 0.3 to 0.6. 
For S1030-based evolution, overnight cultures were inoculated from 
single colonies. The next day, selection cultures were prepared with 
a 100-fold dilution of the overnight cultures, and cells were grown 
for 3 to 4 hours at 37°C until the OD600 reached 0.3 to 0.6.
Cultures were infected at a desired multiplicity of infection 
(MOI), and a chemical inducer was added where appropriate. 
Cell cultures were incubated for 20 hours at 30°C, 250 rpm (Stuart 
Shaking Incubator SI500). Overnight cultures were centrifuged 
for 10 min at 8000g, and the phage supernatant was used to start a 
new round of evolution. After each round, phage supernatants were 
diluted before infecting TG1 cells carrying an appropriate reporter 
plasmid. Infected cells were selected on ampicillin plates, and single 
colonies were grown overnight in 2× TY medium supplemented 
with ampicillin. Phagemid DNA was purified using the QIAprep 
Spin Miniprep Kit (QIAGEN) and analyzed by sequencing (Eurofins 
Genomics).
Phagemid-assisted continuous evolution
Glass bottles, chemostats, and lagoons connected via biocompatible 
tubing (Cole-Parmer) were autoclaved and cooled down to room 
temperature. The autoclaved chemostats and lagoons were placed 
into two incubators (SID60, Stuart) on individual shakers (Topolino 
Mobil, IKA). Before each experiment, the bioreactor was equili-
brated by pumping 2× TY supplemented with the appropriate anti-
biotics through the system at 20 ml hour−1 (Pharmacia Biotech 
Pump P-1).
S1030 cells carrying the modified helper phage HP-PS-gIII-
gVI, an AP, and, optionally, a mutagenesis plasmid were grown on 
agar plates supplemented with appropriate antibiotics and 1% (w/v) 
d-glucose. The next day, 10-ml cultures were inoculated from single 
colonies, grown overnight at 37°C, 250 rpm, and stored at 4°C. 
Starter cultures were inoculated with a 100-fold dilution of the 
overnight culture and grown at 37°C, 250 rpm, until the OD600 
reached 0.3 to 0.6. Chemostats were filled with 25 ml of this starter 
culture, and cells were grown at 37°C with magnetic stir-bar agita-
tion. The lagoon was filled with 40 ml of the starter culture, and cells 
were infected at a MOI of 4 and 1 mM IPTG was added where 
appropriate. The infected cells were grown at 30°C with magnetic 
stir-bar agitation. The flow rate of 2× TY supplemented with the 
appropriate antibiotics was set to 20 ml hour−1 to provide continuous 
supply of media. IPTG (10 mM) in sterile water was added to the 
lagoon at 2 to 3 ml hour−1 to obtain a final concentration of 1 mM 
for induced mutagenesis (Pharmacia Biotech Pump P-1). Samples 
were taken from the outflow of the lagoon, centrifuged, and super-
natants were stored at 4°C. Samples were serial diluted before in-
fecting TG1 cells with an appropriate reporter plasmid. Phage titers 
were analyzed by selection on ampicillin plates and colony count-
ing. Single colonies were picked and grown overnight in 2× TY 
[ampicillin (100 g ml−1)]. Phagemid DNA was purified using the 
QIAprep Spin Miniprep Kit (QIAGEN) and analyzed by sequenc-
ing (Eurofins Genomics). The DNA sequences of selected TFs are 
listed in fig. S11. For the cIopt/RFP enrichment assay, TG1 cells were 
infected with phage dilutions and plated on ampicillin plates. The 
ratio of white to red colonies was analyzed by colony counting, and 
white colonies were linked to cIopt infection by colony PCR.
-Lactamase reversion assay
TG1 cells were transformed with the reporter plasmid pLA230 and 
(i) cloDF-PBAD-polA-SpecR, (ii) cloDF-PBAD-EPpolA-SpecR, (iii) 
cloDF-PBAD-MP4-SpecR, or (iv) cloDF-PBAD-MP6-SpecR and streaked 
out on LB plates supplemented with spectinomycin, kanamycin, and 
1% (w/v) d-glucose. The plasmid pLA230 (21) carries a -lactamase 
gene with the ochre stop codon TAA at amino acid position 26, 
which is located 230 bp downstream the origin of replication. The 
next day, single colonies were picked and grown to the mid-log 
phase in the presence of 1% d-glucose. Cultures were induced with 
1% (w/v) arabinose and incubated for 24 hours at 37°C, 250 rpm 
(Stuart Shaking Incubator SI500). Cells were diluted and plated on 
LB plates in the presence or absence of ampicillin and 1% d-glucose 
and incubated overnight at 37°C. The ratio of the number of 
ampicillin-resistant colonies divided by the total number of colo-
nies on LB plates was calculated.
Rifampicin resistance assay
TG1 cells were transformed with MP4-SpecR or MP6-SpecR and 
plated on LB plates with the appropriate antibiotics and 1% (w/v) 
d-glucose. The next day, single colonies were picked and grown to 
the mid-log phase in the presence of 1% d-glucose. Next, cultures 
were induced with 1% (w/v) arabinose and incubated for 24 hours 
at 37°C, 250 rpm. Cells were diluted and plated on LB plates with 
1% d-glucose in the presence or absence of rifampicin and incubated 
in the dark for 24 hours at 37°C. The ratio of the number of rifampicin- 
resistant colonies divided by the total number of colonies on LB plates 
was calculated.
RFP mutation assay
S1030 cells carrying HP-PS-gIII-gVI, pJPC12-PS-PM,CS-
RBSBBa_B0034-gVI, and a mutagenesis plasmid (MP4-SpecR, MP6-
SpecR, PLlac-MP6-SpecR) were grown in 2× TY medium supplemented 
with antibiotics and 1% d-glucose until the OD600 reached 0.4 to 0.6. 
Cells were infected with an RFP-carrying phagemid (pLITMUS- 
PBBa_R0010-RFP-PBBa_J23106-gIII) at MOI 1 and cultured in the pres-
ence or absence of an inducer (1% arabinose or 1 mM IPTG) for 
20 hours at 30°C, 250 rpm. Phage supernatants were harvested the 
following day, and experiments were performed for three rounds of 
evolution in batch mode. TG1 cells were infected with diluted phage 
supernatants after each round and streaked out on LB plates supple-
mented with ampicillin. Plates were incubated overnight at 37°C, 
and the following day, white and red colonies were counted and the 
ratio was calculated.
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Reporter assay
TG1 cells were transformed with a pJPC12-derived reporter plasmid 
and a phagemid and selected overnight on agar plates at 37°C. The 
next day, single colonies were picked for each biological replicate 
and grown 3 to 5 hours in 1 ml of 2× TY supplemented with chloram-
phenicol (10 g ml−1) and carbenicillin (10 g ml−1) at 37°C, 250 rpm. 
The cultures were diluted to OD600 0.01, and 150 l was added to 
each well of a 96-well plate. The absorbance at 600 nm, green fluo-
rescence (excitation: 485 nm, emission: 520 nm), and red fluorescence 
(excitation: 585 nm, emission: 625 nm) were measured every 10 min 
in a Tecan Infinite F200 PRO plate reader (37°C, shaking between 
readings) until the E. coli cells reached stationary phase. For data 
analysis, fluorescence readings in the late-exponential phase (OD600 
of 0.2 for pLITMUS, OD600 of 0.9 for pLITMUS*) were used. Both 
absorbance and fluorescence were background corrected. The fluo-
rescence was then normalized for the number of cells by dividing by 
the absorbance. The average of three or four biological replicates 
and the corresponding SD were calculated for each sample.
Analysis of gene circuits
Single colonies from TG1 cells carrying a pJPC12-derived reporter 
plasmid and a p15A-derived TF plasmid were grown for 3 to 4 hours 
in 2 ml of 2× TY supplemented with chloramphenicol (5 g/ml) 
and carbenicillin (5 g/ml). The cultures were diluted to OD600 0.01 
in a total volume of 150 l in each well of a 96-well plate. Arabinose 
(0.01, 0.1, 1, and 2%) and N-(-ketocaproyl)-l-homoserine lactone 
(3OC6-HSL; 0.01, 0.1, 1, and 2 M) were added where appropriate. 
The absorbance at 600 nm, green fluorescence (excitation: 485 nm, 
emission: 520 nm), and red fluorescence (excitation: 585 nm, emis-
sion: 625 nm) were measured every 10 min in a Tecan Infinite F200 
PRO plate reader (37°C, shaking between readings) until the E. coli 
population reached stationary phase. For data analysis, fluorescence 
readings in the mid- to late-exponential phase were used. Both 
absorbance and fluorescence were background corrected. The fluo-
rescence was then normalized for the number of cells by dividing 
by the absorbance. The average of three biological replicates and the 
corresponding SD were calculated for each sample.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/24/eaba2728/DC1
View/request a protocol for this paper from Bio-protocol.
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